Reference
All 125 peptides
Every profile uses the same structure: summary, benefits and side effects, vials and reconstitution, a phase-by-phase dosing table, lifestyle notes, identification and linked research.
5 results
Decapeptide-12
Research Goal: Evaluation of melanogenesis inhibition for the treatment of melasma and post-inflammatory hyperpigmentation.
- Route
- Topical
- Dose
- —
- Cycle
- 12–16 weeks for visible pigment shift
Melanostatin DM
Melanostatin DM is a skin-brightening peptide that inhibits alpha-MSH (the hormone that controls melanin production), effectively lightening skin tone and evening out discoloration without bleaching side effects. It works by blocking the signals that tell melanocytes (pigment cells) to produce melanin, preventing tyrosinase enzyme activation—the critical step in melanin synthesis.
- Route
- Topical
- Dose
- —
- Cycle
- 8–12 weeks
Melanotan 1 (MT1)
MT1
Melanotan 1 is a synthetic melanocortin peptide that dramatically increases melanin production to create a deep, prolonged tan with minimal sun exposure—offering genuine UV protection alongside cosmetic tanning effects. It binds to melanocortin-1 receptors on melanocytes, stimulating both melanocyte proliferation and tyrosinase activity to boost melanin production and skin darkening.
- Route
- Subcutaneous
- Dose
- 500 mcg – 2 mg
- Cycle
- Indefinite during tanning months; requires moderate UV stimulus to activate
Melanotan 2 (MT2)
MT2
Melanotan 2 is a synthetic melanocortin agonist that powerfully stimulates melanin production for rapid, deep tanning while simultaneously boosting libido and sexual function through activation of multiple melanocortin receptors. Unlike Melanotan 1, which primarily targets skin pigmentation via MC1R, MT2 activates MC3R and MC4R in the brain, creating appetite suppression in some users alongside pronounced erectile enhancement and spontaneous arousal—effects that make it uniquely dual-purpose for cosmetic tanning and sexual wellness.
- Route
- Subcutaneous
- Dose
- 250 mcg – 1 mg
- Cycle
- 6–8 weeks
Nonapeptide-1
Research Goal: Evaluation of localized melanin suppression for skin brightening and the treatment of post-inflammatory hyperpigmentation.
- Route
- Topical
- Dose
- —
- Cycle
- 8–12 weeks for observable changes in pigmentation